New MRI contrast agent could aid early stage cancer detection

A new MRI contrast agent shows promise for early detection of metastasizing cancers, particularly liver cancer. Published in Science Advances, the study highlights the agent's ability to detect overexpression of CX CR4 receptors in cancerous organs during early metastasis. Tested in mice, the agent is set for fast-tracked human trials by the FDA. The research involves gadolinium, enhancing MRI detection capabilities.

What is the current status of human trials for the new MRI contrast agent?

What role does gadolinium play in the new contrast agent?